We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Collection of Cerebrospinal Fluid and Tumor Tissue in Subjects With Metastatic Melanoma and Controls

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01312506
Recruitment Status : Withdrawn (Trial experienced funding issues, was never opened to accrual.)
First Posted : March 10, 2011
Last Update Posted : July 27, 2016
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:

This study has two ultimate goals:

  1. Understand how the original melanoma from the skin spreads to the CNS. In order to study this we need to collect (and compare) the original skin melanoma, the CNS melanoma, as well as any other melanoma that has not metastasized to the CNS.
  2. Develop a diagnostic blood test that will early identify subjects at high risk for developing CNS metastasis or patients who may already have CNS metastasis but the MRI or the CAT scan cannot yet detect it. Thus, the investigators plan to collect CSF from subjects like you who have melanoma CNS metastases in order to confirm the presence of this biomarker.

Condition or disease
Metastatic Melanoma CNS Metastases

Study Design

Study Type : Observational
Actual Enrollment : 0 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Procurement of Central Nervous System and Extracranial Tumor Tissues, Cerebrospinal Fluid, and Serum/Plasma From Patients With Metastatic Melanoma to the CNS and Respective Controls for Gene Expression and Proteomic Profiling
Study Start Date : July 2012
Primary Completion Date : July 2012
Study Completion Date : November 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma
U.S. FDA Resources

Groups and Cohorts

Group/Cohort
Subjects undergoing a craniotomy
This group will include those subjects who have consented to have either a craniotomy or a laminectomy to resect an intramedullary tumor.
Metastases, no craniotomy
These subjects have metastases but have either chosen not to undergo removal of the cancer or their neurosurgeon does not recommend surgical approach or they have been diagnosed with metastatic melanoma but do not have CNS metastases.
Healthy Volunteers
Subjects who do not have known melanoma or metastases.


Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Primary care clinic
Criteria

Inclusion Criteria:

  1. Regarding patients with distant metastatic melanoma and established melanoma CNS metastases who are scheduled for craniotomy:

    • Histologically confirmed, primary cutaneous melanoma, metastatic to the CNS (brain OR spinal cord OR carcinomatous meningitis) based on:

      • Pathologic confirmation (i.e. prior craniotomy) OR
      • Radiography (brain MRI or CT scan with intravenous contrast)
    • Patients must have no contraindications for and be able to undergo lumbar puncture for CSF collection
    • Hemoglobin level of 8g/dL or higher. This can be drawn on the day of consent, or will be acceptable if documented from a previous visit within the prior 30 days
    • Subjects must have provided written, informed consent (ICF) prior to any study procedures
    • Subjects must provide a FFPE tissue block containing a biopsy from the primary site
  2. Regarding patients with distant metastatic melanoma and established melanoma CNS metastases who are not having a craniotomy and before they undergo external beam irradiation or stereotactic radiosurgery (patient's and/or neurosurgeon's preference):

    • Histologically confirmed melanoma (unknown primary, mucosal, ocular are allowed), metastatic to the CNS (brain OR spinal cord OR carcinomatous meningitis) based on

      • Pathologic confirmation (i.e. prior craniotomy) and/or
      • Radiography (brain MRI or CT scan with intravenous contrast)
    • Patients must have no contraindications for and be able to undergo lumbar puncture for CSF collection
    • Hemoglobin level of 8g/dL or higher. This can be drawn on the day of consent, or will be acceptable if documented from a previous visit within the prior 30 days
    • Subjects must have provided written ICF prior to any study procedures
  3. Regarding patients who have distant metastatic melanoma without radiographically detectable melanoma CNS metastases but are willing to undergo lumbar puncture:

    • Histologically confirmed melanoma (unknown primary, mucosal, ocular are allowed),
    • Patients must have no contraindications to lumbar puncture
    • Hemoglobin level of 8g/dL or higher. This can be drawn on the day of consent, or will be acceptable, if documented from a previous visit within the prior 30 days
    • Subjects must have provided written ICF prior to any study procedures
  4. Regarding healthy volunteers

    • Patients must have no contraindications to lumbar puncture (see Table 1)
    • Patient must answer NO to all questions listed in Appendix B
    • Hemoglobin level of 8g/dL or higher. This can be drawn on the day of consent or will be acceptable if documented from a previous visit within the prior 30 days
    • Subjects must have provided written, ICF prior to any study procedures

Exclusion Criteria:

  • For study subjects, patients with extradural lesions, i.e. those that originate from the bone (calvarium or vertebrae), will not be considered.
  • Any significant psychiatric disease, medical intervention, or other conditions, which in the opinion of the Investigators, could impair proper discussion of the informed consent or compromise participation to the clinical trial.
  • Active systemic treatment for metastatic melanoma within 2 days from the collection of specimens (brain tumor tissue, peripheral blood, CSF). Corticosteroids, other immunosuppressive anti-inflammatory and anti-epileptic medications are allowed.
  • Patients who have undergone whole brain irradiation therapy within the last 30 days. Therefore neither CNS lesions nor CSF are considered suitable for collection.
  • Patients with growing CNS lesions at an area that has previously undergone radiosurgery within 3 months prior to enrollment in this study. Therefore CNS tumors from previously irradiated areas using radiosurgery are not considered suitable for collection although CSF is allowed for collection.
  • Brain abscess.
  • Patients with new focal findings on neurological examination.
  • Infected skin over the lumbar puncture needle entry site.
  • Other conditions that at the opinion of the investigator are contraindicated.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01312506


Sponsors and Collaborators
University of Pittsburgh
Investigators
Principal Investigator: Stergios Moschos, MD University of Pittsburgh
More Information

Responsible Party: University of Pittsburgh
ClinicalTrials.gov Identifier: NCT01312506     History of Changes
Other Study ID Numbers: 10-067
First Posted: March 10, 2011    Key Record Dates
Last Update Posted: July 27, 2016
Last Verified: July 2016

Keywords provided by University of Pittsburgh:
metastatic
melanoma
CNS

Additional relevant MeSH terms:
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas